Option Investor
Newsletter

ADDITION SEPTEMBER RECOMMENDATIONS 8-27-06

HAVING TROUBLE PRINTING?
Printer friendly version

We are recommending the following two put writes to our SEPTEMBER RECOMMMENDED LIST.

We are recommending put writes on the following issues:

ZGEN - ZymoGenetics is an independent biopharmaceutical company focused on the discovery, development and commercialization of therapeutic proteins for the prevention or treatment of human diseases.

CRME - Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with three late stage clinical drug programs focused on atrial arrhythmias, congestive heart failure, and hyperuricemia (gout). Cardiome's lead antiarrhythmic product, RSD1235, is designed to be an acute-use, intravenous administration treatment for atrial fibrillation, a condition in which the atria of the heart beat rapidly and erratically. RSD1235 selectively blocks ion channels in the heart that are known to be active during episodes of atrial fibrillation

We are recommending the following specific put writes

ZGEN 20.75
SELL SEP 15 PUT = GZU-UC
Target Price $25.00
Potential Profit(10 x = $250.00

Initial Margin $4,400 10 (contracts)
Return on Investment 5.68%
Cost Basis in Stock = $14.75
Days to Expiration = 21
Stock goes on Watch List Price at: $18.75
STOP EXIT STRATEGY
Close option position if Stock CLOSES less than $15.00

CRME $12.88
SELL SEP 10.00 PUT = UXY-UB
Target Price $30.00
Potential Profit(10 x = $300.00
Initial Margin $2,876 10 (contracts)
Return on Investment 10.43%
Cost Basis in Stock = $9.70
Days to Expiration = 21
Stock goes on Watch List Price at: $11.50
STOP EXIT STRATEGY
Close option position if Stock CLOSES less than $10.00


When these positions are filled it should bring our SEPTEMBER POSTIONS to a total of seven (7)

Option Writers Newsletter Archives